Blackstone (BX) has been making significant strides in the marketplace recently. Analysts at Citigroup have revised their price target for Blackstone to $137.00. The company is preparing for a considerable $11 billion property buying spree in Europe and received an upgrade from JMP Securities. In a significant move, Blackstone has hired a former Pfizer scientist to discover blockbusters. It has also recently sealed a $718M deal, acquiring a prime Texas portfolio from Crow Holdings. The company's shares have seen a surge of 14.4%, potentially indicating further gains. Blackstone is expected to make an announcement on quarterly earnings soon and has successfully collected $10.6B of commitments for its new European real estate fund. Among its shareholders, institutions and funds like Fmr LLC have made large commitments. The company has shown promise by securing major real estate deals and attracting bullish sentiments from organisations. With substantial purchases by various investment groups and several price target adjustments by financial firms underline the company's significant role in the market. Blackstone also shows potential for higher dividends, and is also making strides in the commercial real estate sector with a fund of $8 billion. The company is on track to report positive earnings growth for Q4 and is attracting attention for its vast and diversified asset management abilities.
Blackstone BX News Analytics from Sat, 30 Nov 2024 08:00:00 GMT to Sat, 12 Apr 2025 23:42:28 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 2
